, Tracking Stock Market Picks
Enter Symbol:
Rating: PCRX

Pacira Pharmaceuticals Inc (NASDAQ: PCRX) rated to Buy by Nomura

Tuesday,  Sep 29, 2015  10:25 AM ET by Betsy O'Brien Harrison

Nomura rated Pacira
Pharmaceuticals Inc (NASDAQ: PCRX) to Buy.

Pacira Pharmaceuticals, Inc. (Pacira), formerly Pacira, Inc., is the holding company for the Company?s California operating subsidiary of the same name, which it refers to as PPI-California. The Company is a specialty pharmaceutical company focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its product candidate EXPAREL is a long-acting bupivacaine (anesthetic/analgesic) product for postsurgical pain management. EXPAREL provides analgesia for up to 72 hours post-surgery. EXPAREL consists of bupivacaine encapsulated in DepoFoam. DepoFoam, its extended release drug delivery technology, is the basis for its commercial products: DepoCyt(e) and DepoDur, which it manufactures for its commercial partners. Its product portfolio and product candidate pipeline include EXPAREL, DepoCyt, DepoDur, DepoNSAID and DepoMethotrexate.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy